Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA’s Generics Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.